Add office photos
Employer?
Claim Account for FREE
Wockhardt
3.9
based on 1.3k Reviews
Company Overview
Associated Companies
Company Locations
Working at Wockhardt
Company Summary
Overall Rating
3.9/5
based on 1.3k reviews
9% above
industry average
Highly rated for
Work-Life Balance, Company Culture, Skill Development
Critically rated for
Promotions/Appraisal, Salary & Benefits
Work Policy
Work from office
86% employees reported
Monday to Saturday
51% employees reported
Flexible timing
53% employees reported
Within city
39% employees reported
View detailed work policy
Top Employees Benefits
Job/Soft skill training
114 employees reported
Health insurance
110 employees reported
Free meal
88 employees reported
Office cab/shuttle
65 employees reported
View all benefits
About Wockhardt
Founded in1999 (25 yrs old)
India Employee Count5k-10k
Global Employee Count5k-10k
India HeadquartersMumbai, Maharashtra, India
Office Locations
--
Websitewockhardt.com
Primary Industry
Other Industries
--
Are you managing Wockhardt's employer brand? To edit company information,
claim this page for free
Wockhardt is a global pharmaceutical and biotechnology organisation, providing affordable, high-quality medicines for a healthier world. It is India’s leading research-based global healthcare enterprise with relevance in the fields of Pharmaceuticals, Biotechnology and a chain of advanced Super Speciality Hospitals. Wockhardt is a true Indian Multi-National Company with a multi-ethnic workforce of 8600 Wockhardt Associates from 21 different nationalities globally. It has 3 research centres and 12 manufacturing plants, with businesses ranging from the manufacture and marketing of Pharmaceutical and Bio-pharmaceutical formulations, Active Pharmaceutical Ingredients (APIs) and Vaccines.
Managing your company's employer brand?
Claim this Company Page for FREE
Brands of Wockhardt
Wockhardt Foundation
3.6
• 89 reviews
Report error
Wockhardt Subsidiaries
PINEWOOD HEALTHCARE
5.0
• 1 review
Report error
Wockhardt Ratings
based on 1.3k reviews
Overall Rating
3.9/5
How AmbitionBox ratings work?
5
683
4
352
3
145
2
69
1
97
Category Ratings
4.0
Work-Life Balance
3.9
Company Culture
3.9
Skill Development
3.7
Work Satisfaction
3.6
Job Security
3.3
Salary & Benefits
3.1
Promotions/Appraisal
Wockhardt is rated 3.9 out of 5 stars on AmbitionBox, based on 1.3k company reviews.This rating reflects an average employee experience, indicating moderate satisfaction with the company’s work culture, benefits, and career growth opportunities. AmbitionBox gathers authentic employee reviews and ratings, making it a trusted platform for job seekers and employees in India.
Read more
Gender Based Ratings at Wockhardt
based on 1.3k reviews
3.7
Rated by 108 Women
Rated 3.7 for Work-Life Balance and 3.6 for Skill Development
3.9
Rated by 1.2k Men
Rated 4.0 for Work-Life Balance and 4.0 for Company Culture
Work Policy at Wockhardt
based on 67 reviews in last 6 months
Work from office
86%
Hybrid
13%
Permanent work from home
1%
Wockhardt Reviews
Top mentions in Wockhardt Reviews
+ 5 more
Compare Wockhardt with Similar Companies
Change Company | Change Company | Change Company | ||
|---|---|---|---|---|
Overall Rating | 3.9/5 based on 1.3k reviews | 4.1/5 based on 5.5k reviews | 4.1/5 based on 6.5k reviews | 5.0/5 based on 1 reviews |
Highly Rated for | Work-Life balance Company culture Skill development | Salary & Benefits Job Security Skill development | Skill development Salary & Benefits Work-Life balance | Skill development Work-Life balance Salary & Benefits |
Critically Rated for | Promotion/Appraisals Salary & Benefits | No critically rated category | No critically rated category | No critically rated category |
Primary Work Policy | Work from office 86% employees reported | Work from office 87% employees reported | Work from office 72% employees reported | - |
Rating by Women Employees | 3.7 Good rated by 108 women | 4.1 Good rated by 405 women | 4.1 Good rated by 628 women | - no rating available |
Rating by Men Employees | 3.9 Good rated by 1.2k men | 4.1 Good rated by 4.8k men | 4.1 Good rated by 5.5k men | - no rating available |
Job Security | 3.6 Good | 3.9 Good | 3.7 Good | 4.0 Good |
View more
Wockhardt Salaries
3.3
rated by 1.3k employees for salariesKey Account Manager
(139 salaries)
Unlock
₹2.3 L/yr - ₹7.5 L/yr
Research Scientist
(126 salaries)
Unlock
₹5.3 L/yr - ₹18.1 L/yr
Territory Manager
(120 salaries)
Unlock
₹1.8 L/yr - ₹5.2 L/yr
Senior Officer
(105 salaries)
Unlock
₹2 L/yr - ₹6.8 L/yr
Regional Manager
(93 salaries)
Unlock
₹4.2 L/yr - ₹11.7 L/yr
Junior Executive
(89 salaries)
Unlock
₹3.1 L/yr - ₹7 L/yr
Senior Research Associate
(68 salaries)
Unlock
₹2.9 L/yr - ₹8 L/yr
Research Associate
(57 salaries)
Unlock
₹2.5 L/yr - ₹5.5 L/yr
Medical Representative
(57 salaries)
Unlock
₹2 L/yr - ₹5.1 L/yr
Zonal Sales Manager
(54 salaries)
Unlock
₹7.6 L/yr - ₹18 L/yr
Wockhardt Interview Questions
Interview questions by designation
Top Wockhardt interview questions and answers
Get interview-ready with top interview questions
Interview Process at Wockhardt
based on 10 interviews in last 1 year
Interview Experience
4.1
Good
Difficulty level
Moderate
60%
Hard
40%
People are getting interviews through
based on 31 Wockhardt interviews
Job Portal
23%
Referral
19%
Walkin
13%
Company Website
6%
*39% candidates got the interview through other sources
High confidence
Wockhardt Jobs
Wockhardt News
View all
Wockhardt’s Zaynich gives new hope to cancer patient with successful liver transplant
- Zidebactam/Cefepime (WCK 5222) facilitated a successful liver transplant for a cancer patient at Houston Methodist Hospital, Texas.
- The drug helped clear a chronic bile duct infection and led to the patient's discharge from the hospital.
- The patient had failed to respond to other antibiotics before using Zidebactam/Cefepime under compassionate use.
- 45 patients have benefited from the compassionate use of Zidebactam/Cefepime, which is nearing completion of its Phase III study.
HinduBusinessLine | 16 Dec, 2024
Wockhardt Share Price At Life High As Patent Drug Aids US Patient With Transplant Surgery
- Shares of Wockhardt Ltd. hit a life high as its proprietary antibiotic, ZaynichTM, helped a US patient undergo a successful liver transplant and resume chemotherapy.
- The patient, diagnosed with bile duct cancer, developed severe complications that did not respond to advanced antibiotics. Zaynich was used under compassionate use and eradicated the infections within 15 days.
- The drug's innovative β-lactam enhancer mechanism neutralised resistance mechanisms, marking a significant milestone in infection management.
- Wockhardt stock rose as much as 10% during the day to Rs 1,536.60 apiece on the NSE.
Bloomberg Quint | 16 Dec, 2024
Indigenous development of Nafithromycin marks key milestone in AMR battle: Government
- Indigenous development of Nafithromycin, also known as 'Miqnaf,' marks a key milestone in the battle against Antimicrobial Resistance (AMR), according to the Indian government.
- Nafithromycin is a new antibiotic developed by Wockhardt with support from BIRAC.
- It targets Community-Acquired Bacterial Pneumonia (CABP) caused by drug-resistant bacteria.
- The antibiotic is ten times more effective than current treatments and offers a three-day treatment regimen, shortening recovery time and improving patient outcomes.
HinduBusinessLine | 6 Dec, 2024
Stock Recommendations Today: Experts' Views On Canara Bank, Oil India, Tata Steel, Ugro Capital, Wockhardt
- The view is positive on Tata Steel Ltd. at the current level.
- Astha Jain recommends Canara Bank as a good 'buy' with a target of Rs 120-130.
- Astha Jain suggests a buy on Ugro Capital with a price target of Rs 280-290.
- Hem Securities recommends holding on to Wockhardt with an initial price target of Rs 1,500-1,550.
Bloomberg Quint | 3 Dec, 2024
‘Rs 8 Crore Assistance’: Govt Fact Checks Claims On Nafithromycin Antibiotic
- The Department of Biotechnology clarified that Wockhardt invested Rs 500 crore in developing Nafithromycin, with Rs 8 crore financial support from BIRAC for trials.
- The government refuted claims circulating on social media regarding India's first indigenously developed antibiotic, Nafithromycin.
- Debunking the fake news, the Department of Biotechnology stated that the antibiotic has been developed by Wockhardt at an investment of Rs 500 crore, with Rs 8 crore financial assistance from BIRAC.
- Nafithromycin, marketed as Miqnaf, is designed to address antimicrobial resistance and treat Community-Acquired Bacterial Pneumonia.
Bloomberg Quint | 22 Nov, 2024
Stocks that will see action today: November 7
- Kalpataru Projects International approves proposal to raise ₹200 crore through issuance of NCDs
- KIMS Hospitals expands in Kerala with plans to develop new medical facilities
- Indian Gas Exchange reports tripled gas trade volume in October
- Wockhardt launches QIP issue at a floor price of ₹1,162.25 per share
- Polycab India emerges as the lowest bidder for a ₹1,549.66 crore contract from BSNL
- Innova Captab receives drug manufacturing license for upcoming facility in Jammu
- Sterling Tools signs technical collaboration agreement for manufacturing advanced HVDC contactors and relays
- Several companies to announce their results today: Mahindra & Mahindra, Trent, Cummins India, Lupin, and more
HinduBusinessLine | 7 Nov, 2024
Wockhardt Seeks To Raise Rs 1,000 Via Share Sale To Institutions
- Wockhardt Ltd. plans to raise Rs 1,000 crore via share sale to qualified institutional investors, resulting in a 5.57% stake dilution.
- The base issue size is set at Rs 8,000 crore with an additional green show option of Rs 2,000 crore.
- The shares will be issued at a price of Rs 1,105 per share, which is a 4.9% discount to the floor price of Rs 1,162.25 apiece.
- The issue opened on November 6 and is expected to close on November 7, with a possibility of extension.
Bloomberg Quint | 7 Nov, 2024
Powered by
Compare Wockhardt with
Biocon Limited
3.9
Glenmark Pharmaceuticals
4.0
Zydus Lifesciences
4.2
Torrent Pharmaceuticals
3.9
Lupin
4.2
Aurobindo Pharma
4.0
DIVI'S Laboratories
3.8
Dr. Reddy's
4.1
Viatris
4.2
Abbott
4.2
Alembic Pharmaceuticals
4.0
Alkem Laboratories
3.9
Ipca Laboratories
4.0
Ajanta Pharma
4.0
Akums Drugs & Pharmaceuticals Limited
4.3
GlaxoSmithKline Pharmaceuticals
4.1
Cadila Pharmaceuticals
3.5
Pfizer
4.0
Laurus Labs
4.2
Novartis
4.1
Edit your company information by claiming this page
Contribute & help others!
You can choose to be anonymous
Companies Similar to Wockhardt
Sun Pharmaceutical Industries
Healthcare / Pharma, Manufacturing, Analytics & KPO, Pharma
4.1
• 5.5k reviews
Cipla
Manufacturing, Pharma
4.1
• 6.5k reviews
DRJ & CO
Architecture & Interior Design
5.0
• 1 reviews
Biocon Limited
Biotech & Life sciences, Biotechnology
3.9
• 1.8k reviews
Glenmark Pharmaceuticals
Pharma
4.0
• 2.7k reviews
Zydus Lifesciences
Biotech & Life sciences, Pharma
4.2
• 5.8k reviews
Torrent Pharmaceuticals
Pharma
3.9
• 2.4k reviews
Lupin
Biotech & Life sciences, Manufacturing, Pharma
4.2
• 5.8k reviews
Aurobindo Pharma
Healthcare / Pharma, Biotechnology, Pharma
4.0
• 4.6k reviews
DIVI'S Laboratories
Pharma
3.8
• 1.3k reviews
Dr. Reddy's
Clinical Research, Pharma
4.1
• 6.5k reviews
Viatris
Manufacturing, Pharma
4.2
• 3k reviews
Wockhardt FAQs
When was Wockhardt founded?
Where is the Wockhardt headquarters located?
How many employees does Wockhardt have in India?
Does Wockhardt have good work-life balance?
Is Wockhardt good for career growth?
What are the pros and cons of working in Wockhardt?
Stay ahead in your career. Get AmbitionBox app
Helping over 1 Crore job seekers every month in choosing their right fit company
70 Lakh+
Reviews
5 Lakh+
Interviews
4 Crore+
Salaries
1 Cr+
Users/Month
Contribute to help millions
Get AmbitionBox app
Made with ❤️ in India. Trademarks belong to their respective owners. All rights reserved © 2024 Info Edge (India) Ltd.
Follow us
